HITLAB TEAM • January 15, 2025
HITLAB, a leader in health innovation research, has partnered with Vistim Labs, an emerging pioneer in the evaluation of cognitive and neurodegenerative diseases, to validate their AI-powered brain-mapping algorithm for Alzheimer’s Disease progression and treatment response monitoring. This groundbreaking study aims to enhance clinical decision-making ability for precision treatment of Alzheimer’s Disease (AD), Parkinson’s disease (PD), and related neurodegenerative conditions.
James Hamet, CEO of Vistim Labs, said “we could think of no better partner than HITLAB, for helping us bring such a desperately needed technology to physicians and their patients. Knowing when treatments are working and how they can be adjusted will ensure that the right patient has the right treatment at the right time, for the best possible care outcomes.”
With decades of expertise in public health research and digital health validation, HITLAB will oversee the study’s design, execution, and analysis. The study will involve collaboration with neurology experts, partner sites, and other key stakeholders to ensure its success and credibility.
STUDY OBJECTIVES
This study has two primary goals:
- Validating the Algorithm: Testing Vistim Labs’ proprietary EEG medical procedure and analysis algorithms with diverse patient data to confirm precision and accuracy in estimating gold-standard disease endpoints, including PET-derived amyloid/tau biomarkers.
- Enhancing Capabilities: Allowing Vistim Labs’ medical procedure and analysis to generate estimates of full-resolution PET images from a single EEG recording.
The study will integrate two main diagnostic instruments—EEG and PET—to provide comprehensive results. Vistim Labs’ innovative AI-enabled solution utilizes existing, portable medical equipment to streamline the dementia evaluation process and deliver routine, detailed insights into key dementia biomarkers such as amyloid and tau protein levels, brain atrophy, and cognitive performance.
A Transformative Approach to Dementia Care
As lifespans increase, neurodegenerative diseases like Alzheimer’s and mild cognitive impairment (MCI) are becoming more common, yet effective management remains challenging. Current diagnostic tools are often inaccessible, unreliable, and do not provide actionable insights for optimizing treatment.
Vistim Labs addresses these challenges with an AI-driven brain mapping solution that facilitates routine dementia evaluations by tracking neuronal misfires and disease progression. The technology sequentially maps evoked stimulus-response pairs in the brain, providing exceptional insights into disease progression, including sensitive tracking of changes across established endpoints, such as PET imaging and cognitive assessments, to create a comprehensive, reliable, and practical diagnostic framework.
The expected outcomes of this study include:
- Improved Early Detection: Demonstrating the algorithm’s capability to identify subtle changes in brain activity that precede symptomatic evidence.
- Greater Disease Differentiation: Enhancing the ability to differentiate between disease types, subtypes, and stages of progression.
- Precision Monitoring: Facilitating routine and accurate monitoring of disease progression and treatment effectiveness.
- Optimized Treatment Pathways: Enabling clinicians to make data-driven decisions, prescribing the most effective therapies based on individual patient profiles.
The Path Forward
By validating Vistim Labs’ AI-powered algorithm, HITLAB aims to provide substantial evidence of its efficacy and clinical utility. The study’s findings will offer actionable insights for researchers, clinicians, and policymakers striving to improve dementia care.
The results will also support Vistim Labs’ mission to make dementia evaluation more accessible and empower physicians globally with advanced diagnostic tools. Together, HITLAB and Vistim Labs are working towards a future where cognitive disorders are detected earlier, monitored more effectively, and treated with greater precision.
If you are a neurologist interested in participating in this study, click here.
About Vistim Labs
Vistim Labs leverages advanced AI software to deliver high-resolution insights into neurodegenerative diseases. By integrating EEG with traditional imaging and cognitive testing, their technology offers an innovative, cost-effective approach to dementia evaluation and monitoring. Vistim Labs envisions a new standard of care, where routine and reliable assessments enable earlier intervention and better care outcomes for patients and families worldwide.
Learn more about
